SA
Sign upLog In
ANNX

Annexon, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases by targeting the complement system. Its lead product candidate, ANX005, is in clinical trials for conditions such as Alzheimer's disease and Guillain-Barré syndrome, which positions it uniquely in the CNS therapeutic landscape.

HealthcareBiotechnologylow - the company currently has no revenue and high fixed costs associated with R&D.

Business Overview

01Product sales from ANX005 (0% of total as currently in development)
02Collaborative research agreements (0% of total as no revenue currently)
03Grants and funding for clinical trials (0% of total as no revenue currently)

Annexon primarily aims to generate revenue through the commercialization of its therapies once they receive regulatory approval. The company has a strong focus on the complement system, which is a unique approach in treating neurodegenerative diseases, potentially giving it a competitive edge in a crowded market.

What Moves the Stock

Clinical trial results for ANX005, particularly Phase 2 data expected in late 2026

Partnership announcements with larger pharmaceutical companies for development and commercialization

Regulatory approvals from the FDA for its lead candidates

Market sentiment regarding the neurodegenerative disease treatment landscape

Watch on Earnings
Clinical trial progress updatesCash burn ratePartnership revenue potential

Risk Factors

Regulatory changes that could impact drug approval processes

Technological advancements by competitors that could render its therapies less effective

Emergence of alternative therapies targeting similar neurodegenerative diseases

Increased competition from established pharmaceutical companies entering the CNS space

High cash burn rate leading to potential liquidity issues if funding is not secured

Dependence on external financing for ongoing clinical trials

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - as a biotechnology firm, its performance is less correlated with the economic cycle and more dependent on clinical outcomes and regulatory approvals.

Interest Rates

Moderate - rising interest rates could increase the cost of capital for funding R&D, but the company is currently not reliant on debt financing.

Credit

minimal - the company has low debt levels, which reduces its exposure to credit market fluctuations.

Live Conditions
S&P 500 FuturesRussell 2000 FuturesDow Jones Futures

Profile

growth - investors looking for high-risk, high-reward opportunities in biotech.

high - the stock has shown significant volatility, with a 1-year return of 163.2%.

Key Metrics to Watch
Clinical trial enrollment rates for ANX005
Cash runway (months until funding is needed)
Partnership announcements and their potential financial impact
Regulatory feedback from the FDA on clinical trials

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.